Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 1 results out of 1
Data Insights
FG-3246 by FibroGen for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval
FG-3246 is under clinical development by FibroGen and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to...